Related Experiment Videos
Immunological parameters during treatment with ditiocarb (Imuthiol)
G L Vanham1, L Kestens, J Van Hoof
1Institute of Tropical Medicine, Antwerp, Belgium.
AIDS (London, England)
|April 1, 1993
Summary
Ditiocarb (DTC) did not improve immunological parameters in HIV infection. This study found no beneficial immunomodulatory effects of DTC on T-cell function or viral load markers.
Area of Science:
- Immunology
- Virology
- Pharmacology
Background:
- Human Immunodeficiency Virus (HIV) infection significantly impacts the immune system, particularly T-cells.
- Ditiocarb (DTC) is a drug investigated for its potential immunomodulatory effects.
- Understanding DTC's impact on HIV-related immune dysregulation is crucial for therapeutic development.
Purpose of the Study:
- To evaluate the efficacy of ditiocarb (DTC) in modulating immunological parameters in patients with HIV infection.
- To assess DTC's effect on T-cell counts, activation markers, function (proliferation and cytotoxicity), and viral markers.
Main Methods:
- A double-blind, placebo-controlled study involving 50 HIV-seropositive patients over 4 months.
- Immunophenotyping using flow cytometry to analyze CD4+ T-cells and CD8+ T-cell activation markers (HLA-DR, CD38, CD45RO, CD57).
- Assays for anti-CD3-induced T-cell proliferation and anti-CD3-mediated cytotoxicity; monitoring of HIV antigen and anti-p24 antibody levels.
Main Results:
- DTC treatment showed no significant effect on CD4+ or CD8+ T-cell counts or general CD8+ T-cell activation markers.
- A selective increase in HLA-DR expressing CD8+ cells was noted in the DTC group.
- Both DTC and placebo groups exhibited a decline in T-cell proliferation and a rise in T-cell cytotoxicity; no changes in viral markers or clinical complications were observed.
Conclusions:
- Ditiocarb (DTC) demonstrated no beneficial immunomodulatory effect in HIV-infected patients.
- The study did not support the use of DTC for improving immune status in HIV infection.